444 related articles for article (PubMed ID: 33445986)
1. A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts.
Chernobrovkin AL; Cázares-Körner C; Friman T; Caballero IM; Amadio D; Martinez Molina D
SLAS Discov; 2021 Apr; 26(4):534-546. PubMed ID: 33445986
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
3. The Vital Role of Proteomics in Characterizing Novel Protein Degraders.
Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM
SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886
[TBL] [Abstract][Full Text] [Related]
4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics.
Simard JR; Lee L; Vieux E; Improgo R; Tieu T; Phillips AJ; Fisher SL; Pollock RM; Park E
SLAS Discov; 2021 Apr; 26(4):503-517. PubMed ID: 33430712
[TBL] [Abstract][Full Text] [Related]
6. Target Validation Using PROTACs: Applying the Four Pillars Framework.
Nowak RP; Jones LH
SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
[TBL] [Abstract][Full Text] [Related]
7. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
9. Targeted protein degradation via intramolecular bivalent glues.
Hsia O; Hinterndorfer M; Cowan AD; Iso K; Ishida T; Sundaramoorthy R; Nakasone MA; Imrichova H; Schätz C; Rukavina A; Husnjak K; Wegner M; Correa-Sáez A; Craigon C; Casement R; Maniaci C; Testa A; Kaulich M; Dikic I; Winter GE; Ciulli A
Nature; 2024 Mar; 627(8002):204-211. PubMed ID: 38383787
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
11. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
12. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
13. Targeted protein degradation and the enzymology of degraders.
Fisher SL; Phillips AJ
Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
[TBL] [Abstract][Full Text] [Related]
14. Applications of protein ubiquitylation and deubiquitylation in drug discovery.
Chen Y; Xue H; Jin J
J Biol Chem; 2024 May; 300(5):107264. PubMed ID: 38582446
[TBL] [Abstract][Full Text] [Related]
15. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
16. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
17. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
19. Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic.
Sasso JM; Tenchov R; Wang D; Johnson LS; Wang X; Zhou QA
Biochemistry; 2023 Feb; 62(3):601-623. PubMed ID: 35856839
[TBL] [Abstract][Full Text] [Related]
20. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]